Charles River Laboratories International Inc
criver.comCharles River Laboratories International (NYSE: CRL) is a contract research organization that provides drug discovery, preclinical, and safety testing services to pharmaceutical, biotechnology, and medical device companies. It makes money through fee-for-service contracts covering laboratory animal research models, safety assessment studies, and drug discovery support. The company operates three reported segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. Its customers include large pharmaceutical companies, emerging biotechs, and government and academic institutions that outsource early-stage drug development work rather than build the capability in-house. Non-human primate supply chain availability is cited in the FY2025 10-K as a material operational risk, indicating the centrality of animal research models to the business. The filing covers fiscal year 2025, with the 10-K filed February 18, 2026.
Products & Services
Research models and services (including laboratory rodents and non-human primates), discovery and safety assessment studies (preclinical toxicology, pharmacology), and manufacturing solutions (biologics testing, microbial solutions, cell and gene therapy support).
Revenue Model
Fee-for-service contracts across preclinical research, safety assessment, and manufacturing support services. Revenue is transactional and study-based, tied to volume of studies, animal model sales, and testing services performed for biopharma clients.
Customers & Markets
Pharmaceutical companies, biotechnology companies, medical device companies, government agencies, and academic institutions. End markets are early-stage drug development and regulatory-required safety testing. Customer concentration data not extractable from the provided filing excerpts.
Geographic Exposure
Geographic revenue breakdown not extractable from the provided filing excerpts.
Financial Snapshot
Loading...
